High clinical interest in Medtronic's CoreValve, but pacemaker snag looms?
This article was originally published in Clinica
Executive Summary
US doctors are showing “significant interest” in Medtronic’s transcatheter aortic valve CoreValve, according to Jefferies analyst Raj Denhoy, as the company gears up to present data at the annual Transcathether Cardiovascular Therapeutics (TCT) meeting. The conference is being held in San Francisco, California, next week, and the results will mark “the first randomized look at CoreValve.”